Australia markets closed

    +39.40 (+0.49%)

    -0.0021 (-0.31%)
  • ASX 200

    +34.20 (+0.44%)
  • OIL

    -0.54 (-0.69%)
  • GOLD

    -28.50 (-1.21%)
  • Bitcoin AUD

    +110.16 (+0.11%)
  • CMC Crypto 200

    +15.11 (+1.07%)

Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

Aeglea BioTherapeutics (NASDAQ:AGLE) First Quarter 2023 Results

Key Financial Results

  • Net loss: US$18.4m (loss narrowed by 25% from 1Q 2022).

  • US$0.20 loss per share (improved from US$0.37 loss in 1Q 2022).


All figures shown in the chart above are for the trailing 12 month (TTM) period

Aeglea BioTherapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 136%. Earnings per share (EPS) missed analyst estimates by 14%.

Looking ahead, revenue is expected to decline by 55% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.


Performance of the American Biotechs industry.

The company's shares are down 4.3% from a week ago.

Risk Analysis

You should learn about the 7 warning signs we've spotted with Aeglea BioTherapeutics (including 2 which are a bit unpleasant).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here